Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-HER2 immune stimulator-antibody conjugate NJH395

An immune stimulator-antibody conjugate (ISAC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a not yet disclosed immune stimulator, with potential antineoplastic and immunostimulating activities. Upon administration of the anti-HER2 immune stimulator-antibody conjugate NJH395, the antibody moiety targets and binds to HER2 expressed on tumor cells. Upon antibody/antigen binding, the immune-stimulating moiety may, through an as of yet undisclosed mechanism, enhance the immune-mediated killing of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed in many cancer types and plays a key role in tumor cell proliferation and tumor vascularization.
Synonym:anti-HER2 ISAC NJH395
Code name:NJH 395
NJH-395
NJH395
NJH395
Search NCI's Drug Dictionary